Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

McClung, Michael R.; Balske, A.; Burgio, David E.; Wenderoth, Dietrich; Recker, Robert R.

doi:10.1007/s00198-012-2175-7

Cited by 43 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 722 participants completed 2 years of treatment 29. Both groups receiving weekly DR risedronate demonstrated BMD increases at the lumbar spine and total hip similar to or greater than that with the risedronate 5 mg IR daily dose group (Figure 5A).…”

Section: Clinical Data: Once a Week Risedronate 35 Mg Drmentioning

confidence: 93%

Eliminating the need for fasting with oral administration of bisphosphonates

Pazianas¹,

Abrahamsen²,

Ferrari³

et al. 2013

TCRM

View full text Add to dashboard Cite

Bisphosphonates are the major treatment of choice for osteoporosis, given that they are attached preferentially by bone and significantly reduce the risk of fractures. Oral bisphosphonates are poorly absorbed (usually less than 1% for nitrogen-containing bisphosphonates) and when taken with food or beverages create complexes that cannot be absorbed. For this reason, they must be taken on an empty stomach, and a period of up to 2 hours must elapse before the consumption of any food or drink other than plain water. This routine is not only inconvenient but can lead to discontinuation of treatment, and when mistakenly taken with food, may result in misdiagnosis of resistance to or failure of treatment. The development of an enteric-coated delayed-release formulation of risedronate with the addition of the calcium chelator, ethylenediaminetetraacetic acid (EDTA), a widely used food stabilizer, eliminates the need for fasting without affecting the bioavailability of risedronate or its efficacy.

show abstract

Section: Clinical Data: Once a Week Risedronate 35 Mg Drmentioning

confidence: 93%

Eliminating the need for fasting with oral administration of bisphosphonates

Pazianas¹,

Abrahamsen²,

Ferrari³

et al. 2013

TCRM

View full text Add to dashboard Cite

show abstract

“…The EDTA (chelating agent) is intended to reduce the binding of risedronate to dietary calcium. In a 2 year randomized controlled study, Risedronate DR 35 mg (Delayed Release) given weekly compared with Risedronate IR 5 mg (Instant Release) showed that Risedronate 35 mg DR weekly is as effective as risedronate 5 mg IR daily in increasing spine and hip BMD, so it is approved for use although there is no fracture data (81). …”

Section: Anti-resorptive Agentsmentioning

confidence: 99%

Prevention and treatment of postmenopausal osteoporosis

Tella

Gallagher

2014

The Journal of Steroid Biochemistry and Molecular Biology

650

475

View full text Add to dashboard Cite

In the beginning, that is from the 1960's, when a link between menopause and osteoporosis was first identified; estrogen treatment was the standard for preventing bone loss, however there was no fracture data, even though it was thought to be effective. This continued until the Women's Health Initiative (WHI) study in 2001 that published data on 6 years of treatment with hormone therapy that showed an increase in heart attacks and breast cancer. Even though the risks were small, 1 per 1500 users annually, patients were worried and there was a large drop off in estrogen use. In later analyses the WHI study showed that estrogen reduced fractures and actually prevented heart attacks in the 50-60 year age group. Estrogen alone appeared to be safer to use than estrogen + the progestin medroxyprogesterone acetate and actually reduced breast cancer.

show abstract

“…Divers schémas posologiques oraux de risédronate sont approuvés aux fins de la prévention et de la prise en charge de l'ostéoporose : 5 mg par jour, 35 mg par semaine ou 150 mg par mois. Le risédronate à libération différée peut être administré avec des aliments selon une posologie de 35 mg par semaine et est aussi efficace et aussi bien toléré que le risédronate administré à raison de 5 mg par jour 56 .…”

Section: Risédronateunclassified